{"id":"W4402560719","doi":"10.1016/j.annonc.2024.08.1025","title":"965MO Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Lenvatinib; Nivolumab; Ipilimumab; Hepatocellular carcinoma; Sorafenib; Internal medicine; Oncology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001788486,0.0006596825,0.001150089,0.0003961027,0.0002421864,0.001061064,0.0006168984,0.0006979333,0.007199659],"category_scores_gemma":[0.002055852,0.0002848963,0.004334855,0.0004887131,0.0002909232,0.0009169988,0.0006133511,0.001718512,0.0008888087],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001064568,"about_ca_system_score_gemma":0.0009571858,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003332672,"about_ca_topic_score_gemma":0.01101405,"domain_scores_codex":[0.999207,0.0003712606,0.00004203302,0.0001553208,0.00006992478,0.0001545064],"domain_scores_gemma":[0.9987566,0.0004375101,0.0003000071,0.0001531015,0.00005760592,0.000295046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8203605,0.003247227,0.07019786,0.001079466,0.01739389,0.0001016909,0.0001053323,0.002116931,0.004813839,0.0002613054,0.009764129,0.07055788],"study_design_scores_gemma":[0.2596084,0.1187217,0.5377885,0.0007206317,0.04974605,0.0004776916,0.0004101551,0.004667932,0.004944391,0.001337597,0.02142771,0.0001491976],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9773737,0.005997405,0.0003305343,0.0007301177,0.0001797128,0.0002571757,0.01202719,0.00007652597,0.003027642],"genre_scores_gemma":[0.9817099,0.001987008,0.0005605797,0.0008366102,0.0001681002,0.0002605452,0.0116254,0.00003649402,0.002815417],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007199659,"threshold_uncertainty_score":0.02408522,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.375544513528456,"score_gpt":0.4327875688777922,"score_spread":0.05724305534933621,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}